Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

From Detection to Prediction: Toward Prevention of Structural Progression in Rheumatoid Arthritis

Shigeru Ohno
The Journal of Rheumatology November 2026, 53 (11) 1171-1172; DOI: https://doi.org/10.3899/jrheum.2026-0805
Shigeru Ohno
1S.O. Ohno, MD, PhD, Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ohno{at}yokohama-cu.ac.jp
  • Article
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Imaging has long played an essential role in the diagnosis and management of rheumatoid arthritis (RA). Conventional radiography has been used primarily to document structural damage, whereas musculoskeletal ultrasound (MSUS) and magnetic resonance imaging (MRI) have enabled us to visualize inflammation at a much earlier stage. The challenge now is to determine how these imaging modalities can be best incorporated into clinical practice, not simply to detect abnormalities but to identify patients and joints at risk of future structural damage.

New technologies often follow a familiar trajectory: initial enthusiasm, subsequent disappointment, and eventually, a more balanced appreciation of their true value. In RA, enthusiasm for MSUS-guided treatment strategies was tempered by the results of the Clinical Tight Control Therapy (ARCTIC) and Targeting Synovitis in Early Rheumatoid Arthritis (TaSER) trials, both of which failed to demonstrate superior clinical or structural outcomes with systematic ultrasound-driven treat-to-target strategies.1,2 These findings appropriately cautioned against indiscriminate escalation of treatment based solely on imaging abnormalities. However, they should not be interpreted as evidence that MSUS has little prognostic value. Rather, these findings may indicate that we have been asking the wrong question: not whether ultrasound should guide treatment in every patient, but in which patients, for what purpose, and at what time.

In this issue of The Journal of Rheumatology, Nakagawa et al provide an important contribution to this evolving perspective.3 In treatment-naïve patients with early RA, the presence of intraerosive power Doppler (PD) signals on baseline MSUS was independently associated with radiographic progression at 1 year, whereas conventional clinical and laboratory measures, including disease activity indices, were not. The finding that a specific ultrasound feature was more informative than global measures of disease activity is particularly intriguing. It suggests that the biological processes occurring within individual joints may contain prognostic information that is not captured by patient-level assessments.

The concept itself is not entirely new. Previous studies have shown that residual synovitis detected by ultrasound is associated with subsequent flare and structural progression, even in patients who meet clinical criteria for remission.4,5 In particular, PD signals located in contact with or penetrating the bone cortex have been associated with subsequent radiographic progression in patients in clinical remission.6 Quantitative PD measures have also demonstrated the potential to stratify the risk of structural deterioration in early RA.7 Taken together, these observations suggest that ultrasound may provide more than a snapshot of current inflammation; it may also offer a window into the future behavior of individual joints.

Nevertheless, the findings of Nakagawa et al3 should not be interpreted as evidence that every joint with an intraerosive PD signal requires immediate treatment intensification. Their data also highlight an important limitation of prediction. Among the anatomical units with baseline intraerosive PD signals, only a minority subsequently demonstrated radiographic erosion progression. Indeed, many units with intraerosive PD signals did not develop radiographic progression during follow-up. Conversely, only a proportion of joints that ultimately progressed had shown intraerosive PD signals at baseline. Thus, although this finding that intraerosive PD signal is strongly associated with subsequent damage, its positive predictive value and sensitivity remain insufficient for it to function as a standalone treatment trigger.3

This distinction is critical. Predicting disease does not automatically justify treating every predictive abnormality. The experience with ultrasound-guided treat-to-target strategies has already taught us that detecting more inflammation does not necessarily translate into better outcomes when treatment is escalated indiscriminately.1,2 The clinical value of a prognostic biomarker therefore depends not only on its statistical association with an outcome but also on whether acting on that information improves the balance between the benefits and harms of treatment.

An alternative approach may be to regard intraerosive PD signals as one component of a risk-stratification strategy. Rather than treating a PD signal itself as a therapeutic target, clinicians could use its presence, together with clinical disease activity, serological risk factors, existing structural damage, and longitudinal imaging findings, to identify joints or patients who warrant closer surveillance or reconsideration of treatment adequacy. Importantly, the findings of Nakagawa et al3 also raise the possibility that serial MSUS examinations may be more informative than a single baseline examination. Persistent or recurrent vascular signals may provide a more robust indication of ongoing destructive activity than that of a single observation.

This perspective represents a subtle but important shift in the role of imaging in RA. For decades, imaging primarily documented what had already happened. Radiographs showed accumulated damage, whereas ultrasound and MRI subsequently allowed us to detect inflammation that was clinically occult. The next step is prediction, namely, identifying which apparently vulnerable joints are most likely to become damaged. The goal, however, should not be prediction for its own sake. It should be prevention.

The message is therefore not “ultrasound instead of clinical assessment,” but rather “ultrasound in addition to clinical assessment, when it can answer a clinically meaningful question.” As Caporali and Smolen pointed out several years ago, current evidence does not support routine ultrasound-driven treatment decisions in all patients with RA.8 However, the limitations of a treatment strategy should not be confused with the limitations of the technology itself. The emerging evidence suggests that MSUS may have a valuable role in identifying high-risk joints and refining prognostic assessment.

The future of ultrasound in RA may therefore lie not in detecting more abnormalities but in identifying the abnormalities that matter. From detection to prediction, the next challenge is to determine whether this predictive information can ultimately be translated into better decisions and, most importantly, into prevention of irreversible structural damage.

Footnotes

  • See Intraerosive PD signals, page 1188

  • DECLARATION OF AI USE

    Generative AI (ChatGPT, GPT-5.6 Luna; OpenAI) was used to assist with translation, language editing, and organization of the manuscript. The author critically reviewed and revised all AI-assisted content, verified the cited references, and takes full responsibility for the accuracy and integrity of the final manuscript.

  • FUNDING

    The author declares no funding or support for this work.

  • COMPETING INTERESTS

    The author declares no conflicts of interest relevant to this article.

  • Copyright © 2026 by the Journal of Rheumatology

REFERENCES

  1. 1.↵
    1. Haavardsholm EA,
    2. Aga AB,
    3. Olsen IC, et al
    . Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ 2016;354:i4205.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Dale J,
    2. Stirling A,
    3. Zhang R, et al
    . Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann Rheum Dis 2016;75:1043-50.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Nakagawa I,
    2. Tanimura S,
    3. Omori S, et al
    . Association of intra-erosive power Doppler signals detected by musculoskeletal ultrasound with 1-year radiographic progression in early rheumatoid arthritis. J Rheumatol 2026;53:1188-95.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Nguyen H,
    2. Ruyssen-Witrand A,
    3. Gandjbakhch F,
    4. Constantin A,
    5. Foltz V,
    6. Cantagrel A.
    Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology 2014;53:2110-8.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Fukae J,
    2. Isobe M,
    3. Kitano A, et al
    . Positive synovial vascularity in patients with low disease activity indicates smouldering inflammation leading to joint damage in rheumatoid arthritis: time-integrated joint inflammation estimated by synovial vascularity in each finger joint. Rheumatology 2013;52:523-8.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Raffeiner B,
    2. Grisan E,
    3. Botsios C, et al
    . Grade and location of power Doppler are predictive of damage progression in rheumatoid arthritis patients in clinical remission by anti-tumour necrosis factor α. Rheumatology 2017;56:1320-5.
    OpenUrlPubMed
  7. 7.↵
    1. Sreerangaiah D,
    2. Grayer M,
    3. Fisher BA,
    4. Ho M,
    5. Abraham S,
    6. Taylor PC.
    Quantitative power Doppler ultrasound measures of peripheral joint synovitis in poor prognosis early rheumatoid arthritis predict radiographic progression. Rheumatology 2016;55:89-93.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Caporali R,
    2. Smolen JS.
    Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis management. Ann Rheum Dis 2018;77:18-20.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology: 53 (11)
The Journal of Rheumatology
Vol. 53, Issue 11
1 Nov 2026
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
From Detection to Prediction: Toward Prevention of Structural Progression in Rheumatoid Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
From Detection to Prediction: Toward Prevention of Structural Progression in Rheumatoid Arthritis
Shigeru Ohno
The Journal of Rheumatology Nov 2026, 53 (11) 1171-1172; DOI: 10.3899/jrheum.2026-0805

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
From Detection to Prediction: Toward Prevention of Structural Progression in Rheumatoid Arthritis
Shigeru Ohno
The Journal of Rheumatology Nov 2026, 53 (11) 1171-1172; DOI: 10.3899/jrheum.2026-0805
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Barriers to Comorbidity Management in Young People With Rheumatic Disease
  • Difficult-to-Manage Axial Spondyloarthritis: One Definition, Multiple Clinical Problems
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire